Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02381288 · ClinicalTrials.gov registry record · Phase 2
Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT02381288 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 17 participants.
The verdict
NCT02381288, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects on serum testosterone (ST) after 6 weeks of subcutaneous (SC) administration of different doses and dosing frequencies of TAK-448 to middle-aged and older men with low ST levels.
Interventions
- DRUG TAK-448
- DRUG TAK-448 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-09-10 |
| Est. Completion | 2016-04-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02381288
The ClinicalTrials.gov registry entry for NCT02381288 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-448 is the first listed.
NCT02381288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02381288 about?
NCT02381288 is a clinical study titled "Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone". The purpose of this study is to evaluate the effects on serum testosterone (ST) after 6 weeks of subcutaneous (SC) administration of different doses and dosing frequencies of TAK-448 to middle-aged and older men with low ST levels.
What is the current status of trial NCT02381288?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2015-09-10. Estimated completion is 2016-04-08.
What interventions are being tested in trial NCT02381288?
The interventions under investigation include: TAK-448 (DRUG), TAK-448 Placebo (DRUG).
Who is sponsoring clinical trial NCT02381288?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.